1254969-09-9

Basic information

• Product Name: 2-[(E)-2-(5-methyl-3-phenyl-isoxazol-4-yl)-vinyl]-thiazole-5-carboxylic acid (tetra-hydro-pyran-4-yl)-amide
• Synonyms: 2-[(E)-2-(5-methyl-3-phenyl-isoxazol-4-yl)-vinyl]-thiazole-5-carboxylic acid (tetra-hydro-pyran-4-yl)-amide
• CAS NO: 1254969-09-9
• Molecular Weight: 395.482
• Mol File: 1254969-09-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-[(E)-2-(5-methyl-3-phenyl-isoxazol-4-yl)-vinyl]-thiazole-5-carboxylic acid (tetra-hydro-pyran-4-yl)-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(E)-2-(5-methyl-3-phenyl-isoxazol-4-yl)-vinyl]-thiazole-5-carboxylic acid (tetra-hydro-pyran-4-yl)-amide(1254969-09-9)
• EPA Substance Registry System: 2-[(E)-2-(5-methyl-3-phenyl-isoxazol-4-yl)-vinyl]-thiazole-5-carboxylic acid (tetra-hydro-pyran-4-yl)-amide(1254969-09-9)

Safety Data

• Hazardous Substances Data: 1254969-09-9(Hazardous Substances Data)

Upstream product

• 79836-78-5 ethyl 2-methylthiazole-5-carboxylate 
• 38041-19-9 4-aminotetrahydropyran 
• 1254970-03-0 2-[(E)-2-(5-methyl-3-phenyl-isoxazol-4-yl)-vinyl]-thiazole-5-carboxylic acid ethyl ester 

Relevant articles and documents

PHARMACEUTICAL FORMULATION FOR TREATING CARDIOVASCULAR DISEASE

The present invention provides a pharmaceutical formulation comprising: an early release portion comprising as a pharmaceutical active ingredient a statin-based hypolipidic agent, an isomer thereof, or a pharmaceutically acceptable salt thereof; and a slow release portion comprising as a pharmaceutical active ingredient a dihydropyridine-based calcium channel blocking agent, an isomer thereof, or a pharmaceutically acceptable salt thereof. When compared with a single formulation of each of the drugs or a simple combination formulation of the drugs, the pharmaceutical formulation according to the present invention comprising an early release portion comprising a statin-based hypolipidic agent and a slow release portion comprising a dihydropyridine-based calcium channel blocking agent is pharmaceutically, scientifically, and economically very useful in preventing or treating cardiovascular disease, pulmonary heart disease, pulmonary disease, or kidney disease of patients who have a metabolic syndrome, insulin resistance, diabetes, or prediabetes. The formulation of the present invention is effective in preventing antagonistic and side effects between the drugs by making the dissolution rate of the statin-based hypolipidic agent different from that of the dihydropyridine-based calcium channel blocking agent, and in facilitating patient compliance in taking the drugs by administering the two different drugs simultaneously.